Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

LRMR

Larimar Therapeutics Inc

Mar 20 • 04:00PM ET

4.49

+0.02 0.45 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN FOLD QURE RPTX ARWR ONCT SRPT CRSP RIGL

| Held by: VTI IWM VXF IWN IBB DFAS VTWO IWC AVSC VTWV

Index	RUT	P/E	-	EPS (ttm)	-2.21	Insider Own	45.67%	Shs Outstand	83.09M	Perf Week	-2.29%
Market Cap	466.43M	Forward P/E	-	EPS next Y	-1.43	Insider Trans	11.85%	Shs Float	57.36M	Perf Month	44.37%
Enterprise Value	333.65M	PEG	-	EPS next Q	-0.53	Inst Own	33.58%	Short Float	13.41%	Perf Quarter	29.77%
Income	-165.67M	P/S	-	EPS this Y	18.18%	Inst Trans	-12.09%	Short Ratio	1.86	Perf Half Y	4.91%
Sales	0.00M	P/B	4.78	EPS next Y	22.81%	ROA	-95.38%	Short Interest	7.69M	Perf YTD	17.85%
Book/sh	0.94	P/C	3.41	EPS next 5Y	29.55%	ROE	-132.59%	52W High	6.42 -30.06%	Perf Year	78.88%
Cash/sh	1.32	P/FCF	-	EPS past 3/5Y	-18.28% 8.67%	ROIC	-204.42%	52W Low	1.61 178.88%	Perf 3Y	-7.04%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.28% 12.33%	Perf 5Y	-75.37%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-69.03%	Oper. Margin	-	ATR (14)	0.45	Perf 10Y	-93.89%
Dividend Ex-Date	-	Quick Ratio	2.19	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	49.95	Recom	1.09
Dividend Gr. 3/5Y	- -	Current Ratio	2.19	EPS Q/Q	-62.43%	SMA20	-8.40%	Beta	1.02	Target Price	16.70
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	13.39%	Rel Volume	0.69	Prev Close	4.47
Employees	71	LT Debt/Eq	0.04	Earnings	Mar 19 BMO	SMA200	19.56%	Avg Volume	4.13M	Price	4.49
IPO	Jun 19, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-49.19% -	Trades		Volume	2,842,528	Change	0.45%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-25	Initiated	Truist	Buy	$18
Oct-16-24	Initiated	Oppenheimer	Outperform	$26
Oct-03-24	Initiated	Wedbush	Outperform	$22
Oct-02-24	Initiated	H.C. Wainwright	Buy	$15
Sep-04-24	Initiated	Robert W. Baird	Outperform	$16
Apr-03-24	Initiated	Leerink Partners	Outperform	$25
Nov-17-23	Upgrade	Citigroup	Neutral → Buy	$4.50
Oct-19-22	Initiated	Guggenheim	Buy	$12
Feb-15-22	Downgrade	William Blair	Outperform → Mkt Perform
Feb-10-21	Initiated	JMP Securities	Mkt Outperform
Feb-01-21	Initiated	William Blair	Outperform	$29

Show Previous Ratings

Mar-19-26 07:22AM	Larimar: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-06-26 10:26AM	LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? (Zacks)
Mar-04-26 04:05PM	Larimar Therapeutics to Participate in Upcoming Investor Conferences in March (GlobeNewswire)
08:50AM	Larimar Therapeutics price target raised to $12 from $11 at Wedbush (TipRanks)
08:59PM	Loading…
Feb-25-26 08:59PM	Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering (GlobeNewswire) +61.25% -7.23%
04:01PM	Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering (GlobeNewswire)
02:30PM	Laminar Therapeutics Stock Is Popping Today: What's Going On? (Benzinga)
Feb-24-26 12:12PM	Larimar Therapeutics (LRMR) Surges On FDA Breakthrough Therapy Designation (Benzinga) +31.32%
07:00AM	Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026 (GlobeNewswire)
Dec-18-25 08:00AM	Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-05-25 07:14AM	Larimar: Q3 Earnings Snapshot (Associated Press Finance) -15.26%
07:00AM	Larimar Therapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-22-25 05:47PM	The Best AI for Picking Stocks, Ranked by Performance (MarketBeat) -8.39%
Oct-09-25 04:14PM	Lost Money on Larimar Therapeutics, Inc. (LRMR)? Possible Fraud - Contact Levi & Korsinsky Today (Newsfile) -5.60%
07:00AM	Loading…
Sep-29-25 07:00AM	Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia (GlobeNewswire) -33.66%
Sep-28-25 05:00PM	Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia (GlobeNewswire)
Aug-14-25 07:13AM	Larimar: Q2 Earnings Snapshot (Associated Press Finance) +14.52%
07:00AM	Larimar Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 04:15PM	Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jul-29-25 11:50PM	Larimar Therapeutics Announces Pricing of Underwritten Public Offering (GlobeNewswire)
04:01PM	Larimar Therapeutics Announces Proposed Underwritten Public Offering (GlobeNewswire)
Jul-17-25 09:11AM	Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics (Zacks)
Jul-16-25 09:01AM	5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats (Zacks)
Jul-08-25 07:00AM	Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia (GlobeNewswire)
Jun-23-25 07:00AM	Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program (GlobeNewswire) -6.56%
Jun-20-25 04:05PM	Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia (GlobeNewswire) -5.47%
May-21-25 11:22AM	Larimar Therapeutics, Inc.'s (LRMR): Analysts See 957% Upside Potential (Insider Monkey) -6.31%
Apr-30-25 07:00AM	Larimar Therapeutics Reports First Quarter 2025 Financial Results (GlobeNewswire) +10.88%
Apr-04-25 01:12PM	Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts (Seeking Alpha)
07:00AM	Loading…
Mar-24-25 07:00AM	Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) -10.24%
Mar-03-25 04:05PM	Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire) -12.54% +5.28%
Jan-23-25 04:05PM	Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia (GlobeNewswire)
Dec-17-24 07:20AM	Larimar Therapeutics announces initial data from OLE study of nomlabofusp (TipRanks) -10.56%
Dec-16-24 07:00AM	Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study and Progress Across Nomlabofusp Program for Friedreich's Ataxia (GlobeNewswire) -21.72%
07:00AM	Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreichs Ataxia (GlobeNewswire)
Nov-18-24 07:00AM	Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024 (GlobeNewswire) -7.92%
Oct-30-24 07:00AM	Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results (GlobeNewswire) +8.74%
Sep-19-24 07:00AM	Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research (GlobeNewswire)
Aug-27-24 08:00AM	Larimar Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-07-24 07:00AM	Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results (GlobeNewswire) -6.54%
May-30-24 04:05PM	Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia (GlobeNewswire) +12.68%
May-22-24 11:25AM	Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study (Zacks)
May-21-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +8.53%
May-20-24 04:05PM	Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia (GlobeNewswire)
May-09-24 01:55PM	LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:00AM	Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results (GlobeNewswire)
Mar-20-24 01:32PM	Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks (Insider Monkey)
Mar-14-24 09:53PM	LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -6.51%
05:32PM	Larimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
04:05PM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development (GlobeNewswire)
Mar-11-24 04:05PM	Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia (GlobeNewswire) -15.39%
Mar-06-24 04:05PM	Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-20-24 01:47PM	Hedge Fund and Insider Trading News: Bill Ackman, George Soros, Arkhouse Management, TYR Capital, Borea Asset Management, Larimar Therapeutics, Inc. (LRMR), and More (Insider Monkey) -5.63%
Feb-19-24 01:48PM	Hedge Fund and Insider Trading News: Bill Ackman, David Tepper, Mark Yusko, Elliott Management, Conestoga Capital Advisors, Larimar Therapeutics Inc (LRMR), Agree Realty Corporation (ADC), and More (Insider Monkey)
Feb-16-24 04:20PM	Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.63%
Feb-14-24 06:15AM	Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock (GlobeNewswire) +36.84%
Feb-13-24 04:18PM	Larimar Therapeutics Announces Proposed Underwritten Public Offering (GlobeNewswire) +11.62%
Feb-12-24 07:00AM	Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia (GlobeNewswire)
Nov-14-23 07:00AM	Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results (GlobeNewswire) +7.11%
Nov-01-23 04:05PM	Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference (GlobeNewswire)
Oct-03-23 04:05PM	Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors (GlobeNewswire) -5.83%
Aug-31-23 04:05PM	Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference (GlobeNewswire)
Aug-10-23 07:00AM	Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results (GlobeNewswire)
Aug-07-23 09:22AM	Larimar Therapeutics Insiders Placed Bullish Bets Worth US$1.2m (Simply Wall St.) -7.19%
Jul-25-23 09:59AM	These 2 Strong Buy Penny Stocks Could Go Boom, Say Analysts (TipRanks) +7.67%
07:00AM	Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial (GlobeNewswire)
Jul-17-23 04:05PM	Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer (GlobeNewswire)
Jun-21-23 04:05PM	Larimar Therapeutics Set to Join Russell 3000® Index (GlobeNewswire)
May-15-23 07:00AM	Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trials 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreichs Ataxia and First Quarter 2023 Financial Results (GlobeNewswire) -29.05%
Mar-28-23 04:05PM	Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days (GlobeNewswire)
Mar-14-23 07:00AM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results (GlobeNewswire)
Feb-07-23 04:05PM	Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer (GlobeNewswire) +6.52% +7.99%
Nov-21-22 04:05PM	Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-10-22 07:00AM	Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results (GlobeNewswire)
Nov-07-22 04:05PM	Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day (GlobeNewswire)
Oct-20-22 08:00AM	Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601 (GlobeNewswire)
Oct-19-22 04:05PM	Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research (GlobeNewswire)
Sep-16-22 01:00PM	Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares (GlobeNewswire) -5.04%
Sep-14-22 07:04AM	Larimar Therapeutics Announces $70 Million Underwritten Offering (GlobeNewswire) +15.56%
07:01AM	Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreichs Ataxia Patients (GlobeNewswire)
Aug-11-22 04:05PM	Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results (GlobeNewswire) +7.07%
Jul-28-22 04:05PM	Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders (GlobeNewswire)
Jun-28-22 08:00AM	Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts (GlobeNewswire)
06:05AM	We're Keeping An Eye On Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Rate (Simply Wall St.)
Jun-02-22 08:00AM	Larimar Therapeutics Announces Upcoming Scientific Conference Presentations (GlobeNewswire)
May-19-22 08:00AM	Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinsons Disease and Movement Disorders Congress (GlobeNewswire)
May-12-22 07:00AM	Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results (GlobeNewswire) -7.91%
Apr-29-22 06:27AM	Despite recent gains, Larimar Therapeutics, Inc. (NASDAQ:LRMR) insiders are still down US$273k after purchasing last year (Simply Wall St.) -5.84%
Apr-13-22 10:40AM	Down 21.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Larimar (LRMR) (Zacks)
Mar-25-22 07:00AM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results (GlobeNewswire)
Feb-16-22 11:57AM	Larimar Therapeutics' stock plunges on FDA decision; could implement cost-cutting measures (American City Business Journals)
Feb-14-22 04:01PM	Larimar Therapeutics Provides Update on CTI-1601 Clinical Program (GlobeNewswire) -52.09%
Jan-19-22 06:53AM	Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Nov-22-21 07:00AM	Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference (GlobeNewswire)
Nov-20-21 08:40AM	In spite of Larimar Therapeutics, Inc.'s recent pullback, insiders still gained about US$85k after buying earlier this year. (Simply Wall St.)
Nov-15-21 07:00AM	Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference (GlobeNewswire)
Nov-12-21 07:00AM	Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results (GlobeNewswire) -8.72%
Sep-16-21 08:00AM	Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event (GlobeNewswire) -7.48%
Sep-02-21 04:01PM	Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference (GlobeNewswire) +5.81%

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Flynn James E	Director	Feb 27 '26	Buy	5.00	5,000,000	25,000,000	10,622,957	Mar 02 07:46 PM
Hamilton Thomas Edward	Director	Feb 27 '26	Buy	5.00	100,000	500,000	664,798	Mar 02 04:30 PM
THOMAS FRANK E	Director	Feb 27 '26	Buy	5.00	5,000	25,000	7,000	Mar 02 04:30 PM
SHERMAN JEFFREY W	Director	Feb 27 '26	Buy	5.00	5,000	25,000	5,000	Mar 02 04:30 PM
Flynn James E	Director	Jul 31 '25	Buy	3.20	9,375,000	30,000,000	9,538,945	Aug 04 06:28 PM

Open in Screener

XERS

Xeris Biopharma Holdings Inc

Mar 20 • 04:00PM ET

5.44

-0.14 -2.51 %

Healthcare • Biotechnology • USA • NASD

XERS Xeris Biopharma Holdings Inc daily Stock Chart

Peers: LGND ALKS BCRX SUPN AMRN ANIP MNKD RDHL ECOR

| Held by: VTI IWM VXF IWO XPH VTWO SCHA VHT IHE FESM

Index	RUT	P/E	-	EPS (ttm)	-0.01	Insider Own	7.16%	Shs Outstand	166.22M	Perf Week	-0.37%
Market Cap	938.03M	Forward P/E	15.48	EPS next Y	0.35	Insider Trans	-2.35%	Shs Float	160.09M	Perf Month	-19.17%
Enterprise Value	1.09B	PEG	-	EPS next Q	0.00	Inst Own	58.77%	Short Float	10.63%	Perf Quarter	-22.17%
Income	0.55M	P/S	3.21	EPS this Y	3641.81%	Inst Trans	2.25%	Short Ratio	8.38	Perf Half Y	-34.46%
Sales	291.85M	P/B	66.05	EPS next Y	192.86%	ROA	0.15%	Short Interest	17.02M	Perf YTD	-30.70%
Book/sh	0.08	P/C	8.45	EPS next 5Y	-	ROE	-	52W High	10.08 -46.03%	Perf Year	0.18%
Cash/sh	0.64	P/FCF	33.59	EPS past 3/5Y	- -	ROIC	0.21%	52W Low	3.81 42.97%	Perf 3Y	321.71%
Dividend Est.	-	EV/EBITDA	28.87	Sales past 3/5Y	38.33% 70.20%	Gross Margin	81.70%	Volatility	4.26% 5.34%	Perf 5Y	22.52%
Dividend TTM	-	EV/Sales	3.72	EPS Y/Y TTM	99.47%	Oper. Margin	8.53%	ATR (14)	0.31	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.57	Sales Y/Y TTM	43.72%	Profit Margin	0.19%	RSI (14)	33.01	Recom	1.43
Dividend Gr. 3/5Y	- -	Current Ratio	2.19	EPS Q/Q	279.30%	SMA20	-8.03%	Beta	0.76	Target Price	11.14
Payout	0.00%	Debt/Eq	18.85	Sales Q/Q	42.78%	SMA50	-19.35%	Rel Volume	1.07	Prev Close	5.58
Employees	435	LT Debt/Eq	18.40	Earnings	Mar 02 BMO	SMA200	-20.96%	Avg Volume	2.03M	Price	5.44
IPO	Jun 21, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	191.26% 4.39%	Trades		Volume	2,166,427	Change	-2.51%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Overweight	$9
Aug-12-25	Resumed	H.C. Wainwright	Buy	$10
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral	$3
Mar-28-24	Initiated	Oppenheimer	Outperform	$5
Aug-28-23	Initiated	Craig Hallum	Buy	$4.50
Oct-21-22	Initiated	Jefferies	Buy	$4
Apr-28-22	Initiated	Craig Hallum	Buy	$6.50
Nov-17-21	Initiated	SVB Leerink	Outperform	$6
Oct-29-21	Initiated	H.C. Wainwright	Buy	$4
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$11
Feb-18-20	Initiated	Piper Sandler	Overweight	$12
Jul-16-18	Initiated	RBC Capital Mkts	Outperform	$24
Jul-16-18	Initiated	Leerink Partners	Outperform	$24
Jul-16-18	Initiated	Jefferies	Buy	$23

Show Previous Ratings

Mar-02-26 04:01PM	Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
12:33PM	Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary (Moby)
10:37AM	Xeris Biopharma Q4 Earnings Call Highlights (MarketBeat)
09:30AM	Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:06AM	Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:13AM	Loading…
07:13AM	Xeris Biopharma: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance (Business Wire)
Feb-27-26 12:29PM	Why Are Shares Of Xeris Biopharma Falling Friday? (Benzinga) -9.20%
Feb-26-26 05:55PM	Xeris Biopharma Subsidiaries File Recorlev Patent Infringement Lawsuit (Business Wire)
12:15PM	BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates (Zacks)
09:15AM	Unlocking Q4 Potential of Xeris Biopharma (XERS): Exploring Wall Street Estimates for Key Metrics (Zacks)
05:35AM	TheStreet Pro: Four Stocks that Will Win Despite Irrational Panic over AI (TipRanks)
Feb-17-26 07:30AM	Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026 (Business Wire)
Jan-08-26 07:00AM	Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue (Business Wire) +12.76%
Jan-02-26 04:15PM	Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -6.37%
07:09PM	Loading…
Dec-31-25 07:09PM	Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday (Motley Fool) +7.39%
Dec-18-25 01:13PM	Xeris Biopharma Holdings, Inc. (XERS): A Bull Case Theory (Insider Monkey)
Dec-01-25 07:00AM	Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application (Business Wire)
Nov-06-25 09:30AM	Xeris Biopharma (XERS) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks) -21.88%
08:30AM	Xeris Biopharma (XERS) Reports Break-Even Earnings for Q3 (Zacks)
07:00AM	Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025 (Business Wire)
Oct-30-25 06:45PM	Plus Therapeutics (PSTV) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Oct-23-25 07:30AM	Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025 (Business Wire)
Oct-20-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Xeris Biopharma (XERS) is a Great Choice (Zacks)
09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue? (Zacks)
Oct-16-25 09:06AM	Xeris Biopharma (XERS) Surges 14.2%: Is This an Indication of Further Gains? (Zacks)
Oct-13-25 07:58AM	Beat the Market the Zacks Way: MariMed, Xeris Biopharma, Lam Research in Focus (Zacks)
Oct-03-25 04:15PM	Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
12:00PM	Xeris Biopharma (XERS) is a Great Momentum Stock: Should You Buy? (Zacks)
09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? (Zacks)
12:00PM	Loading…
Sep-09-25 12:00PM	What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now? (Zacks)
Aug-29-25 05:09AM	Xeris Biopharma Holdings, Inc. (XERS) Reports Record $71.5M Q2 Revenue (Insider Monkey)
Aug-25-25 07:00AM	Xeris Announces Orange Book Listing of U.S. Patent for Recorlev (Business Wire)
Aug-12-25 12:00PM	Xeris Biopharma (XERS) Upgraded to Buy: Here's Why (Zacks)
09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +20.22%
09:30AM	Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:35AM	Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:32AM	Xeris Biopharma: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance (Business Wire)
Jul-31-25 07:30AM	Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
Jul-03-25 08:19AM	Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last? (Zacks)
Jun-03-25 07:30AM	Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day (Business Wire) -7.92%
May-20-25 07:30AM	Xeris Announces Details for Analyst & Investor Day (Business Wire)
May-12-25 03:54PM	Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now (Insider Monkey)
May-09-25 03:21AM	Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
May-08-25 08:20AM	Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +15.18%
07:17AM	Xeris Biopharma: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Record First Quarter 2025 Financial Results (Business Wire)
May-07-25 12:08PM	Xeris Pharmaceuticals Q1 2025 Earnings Preview (Seeking Alpha)
11:51AM	Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings (Seeking Alpha)
May-05-25 05:30PM	Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates (Zacks) -7.33%
May-01-25 07:00AM	Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 (Business Wire)
Apr-22-25 06:46PM	Is Xeris Biopharma Holdings Inc. (XERS) the Best Multibagger Penny Stock to Buy According to Billionaires? (Insider Monkey)
Apr-17-25 07:00AM	Bright Peak Therapeutics Appoints John Schmid to its Board of Directors (GlobeNewswire)
Mar-28-25 08:00AM	Xeris Announces Changes to Its Board of Directors (Business Wire)
Mar-27-25 10:18AM	Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-20-25 10:13AM	Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? (Zacks)
Mar-19-25 04:49PM	Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game (InsiderMonkey) +5.56%
Mar-17-25 08:00AM	Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx (glucagon) for Use as a Diagnostic Aid (Business Wire)
Mar-07-25 02:08AM	Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ... (GuruFocus.com)
Mar-06-25 09:30AM	Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings (Zacks) +9.55%
08:15AM	Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:22AM	Xeris Biopharma: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance (Business Wire)
Feb-27-25 07:00AM	Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025 (Business Wire)
Feb-26-25 10:00AM	Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-24-25 08:00AM	Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer (Business Wire)
Feb-05-25 08:00AM	Xeris to Participate in Upcoming Investor Conferences (Business Wire)
Jan-21-25 09:00AM	The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness (PR Newswire)
Jan-11-25 07:27AM	Xeris Biopharma raises FY24 revenue view to $203M from $198M-$202M (TipRanks)
Jan-10-25 07:00AM	Xeris Expects to Exceed Full-Year 2024 Financial Guidance (Business Wire)
Jan-06-25 04:15PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.37%
Nov-26-24 07:00AM	Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-09-24 02:06AM	Xeris Biopharma Holdings Inc (XERS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Nov-08-24 09:30AM	Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:10AM	Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:10AM	Xeris Biopharma: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Third Quarter 2024 Financial Results (Business Wire)
Oct-31-24 08:00AM	Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024 (Business Wire)
Oct-04-24 04:05PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Aug-22-24 07:00AM	Xeris to Participate in Upcoming Investor Conferences (Business Wire)
Aug-08-24 08:25AM	Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Xeris Biopharma: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-01-24 10:01AM	Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jul-25-24 07:00AM	Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024 (Business Wire) +6.02%
Jul-24-24 09:55AM	Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy? (Zacks) -5.12%
Jul-08-24 07:00AM	Xeris Biopharma Announces CEO Succession Plan (Business Wire)
Jul-03-24 01:05PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jun-03-24 07:00AM	Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev) in Cushings Syndrome Patients at ENDO 2024 (Business Wire) +8.65%
May-30-24 07:30AM	Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121) (Business Wire) +15.03%
07:00AM	Xeris to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-10-24 03:21PM	Xeris Biopharma Holdings Inc (XERS) Q1 2024 Earnings: Revenue Growth Amidst Challenges (GuruFocus.com) -6.38%
12:36PM	Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:27AM	Q1 2024 Xeris Biopharma Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
May-09-24 11:55AM	XERS Stock Earnings: Xeris Biopharma Holdings Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:10AM	Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:11AM	Xeris Biopharma: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events (Business Wire)

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McCulloch Kevin	See Remarks	Mar 12 '26	Option Exercise	4.09	48,898	199,992	1,777,725	Mar 16 06:11 PM
Pieper Steven	See Remarks	Mar 05 '26	Option Exercise	4.71	41,927	197,308	1,408,940	Mar 05 07:18 PM
Hecht Beth	See Remarks	Mar 02 '26	Sale	6.25	16,667	104,086	1,226,507	Mar 04 05:28 PM
BETH HECHT	Officer	Mar 02 '26	Proposed Sale	6.12	66,668	408,008		Mar 02 04:36 PM
Hecht Beth	See Remarks	Feb 02 '26	Sale	7.45	16,667	124,147	1,243,174	Feb 02 06:11 PM
McCulloch Kevin	See Remarks	Jan 08 '26	Sale	8.00	15,000	120,000	1,685,426	Jan 09 05:34 PM
KEVIN MCCULLOCH	Officer	Jan 08 '26	Proposed Sale	7.21	60,000	432,600		Jan 08 04:22 PM
Shannon John Patrick Jr	See Remarks	Jan 05 '26	Option Exercise	1.63	92,301	149,998	2,797,647	Jan 06 06:14 PM
Shannon John Patrick Jr	See Remarks	Jan 05 '26	Sale	7.08	24,907	176,257	2,705,346	Jan 06 06:14 PM
Hecht Beth	See Remarks	Jan 02 '26	Sale	7.43	16,667	123,776	1,308,103	Jan 05 06:01 PM
JOHN H JOHNSON	Director	Dec 19 '25	Proposed Sale	7.22	135,402	977,034		Dec 19 06:15 PM
JOHNSON JOHN	Director	Dec 19 '25	Sale	7.22	135,400	977,019	698,083	Dec 19 05:17 PM
BORMANN-KENNEDY BARBARA-JEAN A	Director	Dec 12 '25	Sale	7.09	15,000	106,414	142,500	Dec 15 05:24 PM
BARBARA-JEAN A BORMANN-KENNEDY	Director	Dec 12 '25	Proposed Sale	7.01	15,000	105,150		Dec 12 04:20 PM
Hecht Beth	See Remarks	Dec 01 '25	Sale	7.01	16,667	116,781	1,320,176	Dec 02 05:14 PM
Shannon John Patrick Jr	See Remarks	Nov 14 '25	Option Exercise	1.55	87,100	135,005	2,730,253	Nov 17 05:58 PM
Shannon John Patrick Jr	See Remarks	Nov 13 '25	Option Exercise	1.55	8,970	13,904	2,666,395	Nov 17 05:58 PM
Shannon John Patrick Jr	See Remarks	Nov 13 '25	Sale	7.46	23,242	173,402	2,643,153	Nov 17 05:58 PM
Hecht Beth	See Remarks	Nov 11 '25	Sale	7.40	16,667	123,296	1,336,843	Nov 13 06:59 PM
JOHN SHANNON	Director	Nov 13 '25	Proposed Sale	7.59	48,149	365,451		Nov 13 04:25 PM
BETH HECHT	Officer	Nov 11 '25	Proposed Sale	7.72	66,668	514,677		Nov 12 07:02 AM
PERSKY MARLA	Director	Sep 11 '25	Sale	7.72	15,500	119,610	142,000	Sep 12 05:09 PM
MARLA PERSKY	Director	Sep 11 '25	Proposed Sale	7.81	15,500	121,055		Sep 11 04:24 PM
SHERMAN JEFFREY W	Director	Aug 28 '25	Option Exercise	6.66	47,040	313,286	261,420	Aug 29 05:21 PM
SHERMAN JEFFREY W	Director	Aug 28 '25	Sale	7.92	42,232	334,515	219,188	Aug 29 05:21 PM
JEFFREY SHERMAN	Director	Aug 28 '25	Proposed Sale	7.92	42,232	334,511		Aug 28 04:09 PM
JOHNSON JOHN	Director	Aug 13 '25	Sale	7.32	107,500	786,459	833,483	Aug 15 04:57 PM
HALKUFF DAWN	Director	Aug 12 '25	Sale	7.28	42,500	309,226	115,000	Aug 13 04:47 PM
JOHN H JOHNSON	Director	Aug 13 '25	Proposed Sale	7.32	107,500	786,452		Aug 13 04:08 PM
DAWN HALKUFF	Director	Aug 12 '25	Proposed Sale	7.28	42,500	309,226		Aug 12 04:23 PM
McCulloch Kevin	See Remarks	Jun 13 '25	Buy	4.38	25,000	109,475	1,708,585	Jun 16 04:26 PM
Fairley Ricki Louise	Director	May 09 '25	Proposed Sale	4.90	56,667	277,668		May 09 05:28 PM

LRMR

Larimar Therapeutics Inc

XERS

Xeris Biopharma Holdings Inc

Upgrade your FINVIZ experience